Business Description
VivoSim Labs Inc
NAICS : 541714
SIC : 2836
ISIN : US68620A1043
Total Employee Number:
9Description
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.43 | |||||
Equity-to-Asset | 0.64 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.59 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -69.63 | |||||
Beneish M-Score | 34.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -63.8 | |||||
3-Year EBITDA Growth Rate | 54.1 | |||||
3-Year EPS without NRI Growth Rate | 23.5 | |||||
3-Year FCF Growth Rate | 19.1 | |||||
3-Year Book Growth Rate | -49 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.44 | |||||
Quick Ratio | 2.44 | |||||
Cash Ratio | 1.73 | |||||
Days Sales Outstanding | 78.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -37.8 | |||||
Shareholder Yield % | -142.89 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -8066.2 | |||||
Net Margin % | -864.09 | |||||
EBITDA Margin % | -689.44 | |||||
FCF Margin % | -7410.4 | |||||
OCF Margin % | -7410.4 | |||||
ROE % | -19.23 | |||||
ROA % | -13.02 | |||||
ROIC % | -361.19 | |||||
3-Year ROIIC % | 178.21 | |||||
ROC (Joel Greenblatt) % | -108.78 | |||||
ROCE % | -18.16 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.63 | |||||
PE Ratio without NRI | 0.63 | |||||
PEG Ratio | 0.02 | |||||
PS Ratio | 16.34 | |||||
PB Ratio | 0.64 | |||||
Price-to-Tangible-Book | 0.64 | |||||
EV-to-EBIT | 0.45 | |||||
EV-to-EBITDA | 0.55 | |||||
EV-to-Revenue | -3.82 | |||||
EV-to-Forward-Revenue | 37.34 | |||||
EV-to-FCF | 0.05 | |||||
Price-to-GF-Value | 0.42 | |||||
Price-to-Graham-Number | 0.13 | |||||
| Price-to-Net-Current-Asset-Value | 0.81 | |||||
| Price-to-Net-Cash | 1.61 | |||||
Earnings Yield (Greenblatt) % | 222.22 | |||||
FCF Yield % | -335.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VivoSim Labs Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.125 | ||
| EPS (TTM) (€) | 1.829 | ||
| Beta | 1.0498 | ||
| 3-Year Sharpe Ratio | -0.51 | ||
| 3-Year Sortino Ratio | -0.78 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 3.492 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 3.492 - 3.492 | ||
| Shares Outstanding (Mil) | 2.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VivoSim Labs Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VivoSim Labs Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-16 09:00 | In 175 days | ||
| Second quarter earnings results for 2027 | 2026-11-06 | In 134 days | ||
| First quarter earnings results for 2027 | 2026-08-12 | In 48 days | ||
| Annual report for 2026 | 2026-06-26 | In 1 day | ||
| Third quarter earnings results for 2026 | 2026-02-11 | 3.49 (+0.00%) | ||
| General meeting for 2025 | 2025-12-16 09:00 | 3.49 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2025-11-06 | 3.49 (+0.00%) | ||
| First quarter earnings results for 2026 | 2025-08-12 | 3.49 (+0.00%) | ||
| Annual report for 2025 | 2025-06-05 | 3.49 (+0.00%) | ||
| 0.0833333:1 Stock Split | 2025-03-21 | 3.49 (+38.24%) |
Show
Entries
VivoSim Labs Inc Frequently Asked Questions
What is VivoSim Labs Inc(FRA:4OR)'s stock price today?
The current price of FRA:4OR is €3.49. The 52 week high of FRA:4OR is €3.49 and 52 week low is €3.49.
When is next earnings date of VivoSim Labs Inc(FRA:4OR)?
The next earnings date of VivoSim Labs Inc(FRA:4OR) is 2026-08-12 Est..
Does VivoSim Labs Inc(FRA:4OR) pay dividends? If so, how much?
VivoSim Labs Inc(FRA:4OR) does not pay dividend.
Press Release
Articles on VivoSim Labs Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers